A high-deductible health plan (HDHP) may incentivize enrollees to limit health care use at the beginning of a plan year, when they are responsible for 100% of costs, or to increase the use of care at the end of the year, when enrollees may have less cost exposure. We investigated both the impact of the deductible reset that occurs at the beginning of a plan year and the option to enroll in an HDHP on the use of substance use disorder (SUD) treatment services over the course of a health plan year. We found decreases in SUD treatment use following the increase in cost exposure related to a deductible reset. There was no variation in this behavior between HDHP offer enrollees and comparison enrollees who were not offered an HDHP. These findings reinforce that cost-sharing poses a barrier to SUD care and continuity of care, which can increase the risk of adverse clinical outcomes.
AgarwalR.MazurenkoO.MenachemiN. (2017). High-deductible health plans reduce health care cost and utilization, including use of needed preventive services. Health Affairs (Millwood), 36(10), 1762–1768. https://doi.org/10.1377/hlthaff.2017.0610
2.
Aron-DineA.EinavL.FinkelsteinA. (2013). The RAND Health Insurance Experiment, three decades later. Journal of Economic Perspectives, 27(1), 197–222. https://doi.org/10.1257/jep.27.1.197
3.
Brot-GoldbergZ. C.ChandraA.HandelB. R.KolstadJ. T. (2017). What does a deductible do? The impact of cost-sharing on health care prices, quantities, and spending dynamics. The Quarterly Journal of Economics, 132(3), 1261–1318. https://doi.org/10.1093/qje/qjx013
Colin CameronA.MillerD. L. (2015). A practitioner’s guide to cluster-robust inference. Journal of Human Resources, 50(2), 317–372. https://doi.org/10.3368/jhr.50.2.317
6.
Department of the Treasury, & Internal Revenue Service. (n.d). Health savings accounts and other tax-favored health plans: For use in preparing 2017 returns. https://www.irs.gov/pub/irs-prior/p969–2017.pdf
7.
DrakeC.AndersonD. M. (2020). Terminating cost-sharing reduction subsidy payments: The impact of marketplace zero-dollar premium plans on enrollment. Health Affairs (Millwood), 39(1), 41–49. https://doi.org/10.1377/hlthaff.2019.00345
8.
DupouyJ.PalmaroA.FatseasM.AuriacombeM.MicallefJ.OustricS.Lapeyre-MestreM. (2017). Mortality associated with time in and out of buprenorphine treatment in French office-based general practice: A 7-year cohort study. Annals of Family Medicine, 15(4), 355–358. https://doi.org/10.1370/afm.2098
9.
EinavL.FinkelsteinA.PolyakovaM. (2018). Private provision of social insurance: Drug-specific price elasticities and cost sharing in Medicare Part D. American Economic Journal: Economic Policy, 10(3), 122–153. https://doi.org/10.1257/pol.20160355
10.
EisenbergM. D.BarryC. L.SchillingC. L.Kennedy-HendricksA. (2020). Financial risk for COVID-19-like respiratory hospitalizations in consumer-directed health plans. American Journal of Preventive Medicine, 59(3), 445–448. https://doi.org/10.1016/j.amepre.2020.05.008
11.
EisenbergM. D.DuS.SenA. P.Kennedy-HendricksA.BarryC. L. (2020). Health care spending by enrollees with substance use and mental health disorders in high-deductible health plans vs traditional plans. JAMA Psychiatry, 77(8), 872–875. https://doi.org/10.1001/jamapsychiatry.2020.0342
12.
EisenbergM. D.HavilandA. M.MehrotraA.HuckfeldtP. J.SoodN. (2017). The long term effects of “Consumer-Directed” health plans on preventive care use. Journal of Health Economics, 55, 61–75. https://doi.org/10.1016/j.jhealeco.2017.06.008
13.
EisenbergM. D.Kennedy-HendricksA.SchillingC.BuschA. B.HuskampH. A.StuartE. A.MeiselbachM. K.BarryC. L. (2022). The impact of HDHPs on service use and spending for substance use disorders. American Journal of Managed Care, 28(10), 530–536. https://doi.org/10.37765/ajmc.2022.89250
GibbonsJ. B.McCulloughJ. S.ZivinK.BrownZ. Y.NortonE. C. (2022). Association between buprenorphine treatment gaps, opioid overdose, and health care spending in US Medicare beneficiaries with opioid use disorder. JAMA Psychiatry, 79(12), 1173–1179. https://doi.org/10.1001/jamapsychiatry.2022.3118
16.
GrossT.LaytonT. J.PrinzD. (2022). The liquidity sensitivity of healthcare consumption: Evidence from social security payments. American Economic Review: Insights, 4(2), 175–190. https://doi.org/10.1257/aeri.20200830
17.
HavilandA. M.EisenbergM. D.MehrotraA.HuckfeldtP. J.SoodN. (2016). Do “Consumer-Directed” health plans bend the cost curve over time?Journal of Health Economics, 46, 33–51. https://doi.org/10.1016/j.jhealeco.2016.01.001
18.
HuckfeldtP. J.HavilandA.MehrotraA.WagnerZ.SoodN. (2015). Patient responses to incentives in consumer-directed health plans- evidence from pharmaceuticals (NBER Working Paper 20927). National Bureau of Economic Research. https://www.nber.org/papers/w20927
Kennedy-HendricksA.SchillingC. J.BuschA. B.StuartE. A.HuskampH. A.MeiselbachM. K.BarryC. L.EisenbergM. D. (2021). Impact of high deductible health plans on continuous buprenorphine treatment for opioid use disorder. Journal of General Internal Medicine, 37, 769–776. https://doi.org/10.1007/s11606-021-07094-9
21.
KirchhoffS. M. (2018). Medicare part D prescription drug benefit. Congressional Research Service.
MoosR.SchaeferJ.AndrassyJ.MoosB. (2001). Outpatient mental health care, self-help groups, and patients’ one-year treatment outcomes. Journal of Clinical Psychology, 57(3), 273–287. https://doi.org/10.1002/jclp.1011
24.
NewhouseJ. P., & Insurance Experiment Group. (1993). Free for all? Lessons from the RAND health insurance experiment. Harvard University Press.
25.
OptumLabs. (2020). Optumlabs and Optumlabs Data Warehouse (OLDW) descriptions and citation.
26.
OuimetteP. C.MoosR. H.FinneyJ. W. (1998). Influence of outpatient treatment and 12-step group involvement on one-year substance abuse treatment outcomes. Journal of Studies on Alcohol and Drugs, 59(5), 513–522. https://doi.org/10.15288/jsa.1998.59.513
27.
ParkY. J.MartinE. G. (2017). Medicare part D’s effects on drug utilization and out-of-pocket costs: A systematic review. Health Services Research, 52(5), 1685–1728. https://doi.org/10.1111/1475-6773.12534
28.
RabideauB.EisenbergM. D.ReidR.SoodN. (2021). Effects of employer-offered high-deductible plans on low-value spending in the privately insured population. Journal of Health Economics, 76, 102424. https://doi.org/10.1016/j.jhealeco.2021.102424
29.
ReutchC.TkaczJ.NadipellV. R.BradyB. L.RonquestN.UnH.VolpicelliJ. (2017). Heterogeneity of nonadherent buprenorphine patients: Subgroup characteristics and outcomes. American Journal of Managed Care, 23(6), 172–179.
30.
SamplesH.WilliamsA. R.CrystalS.OlfsonM. (2020). Impact of long-term buprenorphine treatment on adverse health care outcomes in Medicaid. Health Affairs (Millwood), 39(5), 747–755. https://doi.org/10.1377/hlthaff.2019.01085
31.
SchillingC. J.EisenbergM. D.Kennedy-HendricksA.BuschA. B.HuskampH. A.StuartE. A.MeiselbachM. K.BarryC. L. (2021). Effects of high-deductible health plans on enrollees with mental health conditions with and without substance use disorders. Psychiatric Services, 73, 518–525.
32.
Substance Abuse and Mental Health Services Administration. (2021). Key substance use and mental health indicators in the United States: Results from the 2020 National Survey on Drug Use and Health (HHS Publication No. PEP21-07-01-003, NSDUH Series H-56). https://www.samhsa.gov/data/
33.
Substance Abuse and Mental Health Services Administration. (2022). Key substance use and mental health indicators in the United States: Results from the 2021 National Survey on Drug Use and Health (HHS Publication No. PEP22-07-01-005, NSDUH Series H-57). https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report
WangP. S.PatrickA. R.DormuthC. R.AvornJ.MaclureM.CanningC. F.SchneeweissS. (2008). The impact of cost sharing on antidepressant use among older adults in British Columbia. Psychiatric Services, 59(4), 377–383. https://doi.org/10.1176/ps.2008.59.4.377
36.
ZhangY.DonohueJ. M.NewhouseJ. P.LaveJ. R. (2009). The effects of the coverage gap on drug spending: A closer look at Medicare Part D. Health Affairs (Millwood), 28(2), w317–w325. https://doi.org/10.1377/hlthaff.28.2.w317
37.
ZhengS.RenZ. J.HeinekeJ.GeisslerK. H. (2016). Reductions in diagnostic imaging with high deductible health plans. Medical Care, 54(2), 110–117. https://doi.org/10.1097/MLR.0000000000000472
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
